Search Results 491-500 of 1992 for ai学习网,ai 写作网,ai绘画插画网站,ai智能聊天网站,ai智能网页,等欢迎访问豌豆Ai站群搜索引擎系统官方网站:www.wd.chat

  1. A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma - Mayo Clinic

    About this study. This study aims to demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior ...

  2. A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) - Mayo Clinic

    Clinical Trials · A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301).

  3. MMRC Horizon One Adaptive Platform Trial Evaluating Therapies In RRMM - Mayo Clinic

    Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different ...

  4. A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma - Mayo Clinic

    This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with ...

  5. A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma - Mayo Clinic

    About this study. The primary objectives of this study are to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib + ...

  6. Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid Leukemia - Mayo Clinic

    In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression. If a complete response is observed, ...

  7. About This Site - Mayo Clinic

    terms-conditions-use-policy · Blood Donor Program · Frequently asked questions · Platelet, double red blood cell and plasma donations · Minnesota Blood Donor ...

  8. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual ...

  9. A Study to Evaluate Mesenchymal Stem Cells for Reducing Anastomotic Stenosis - Mayo Clinic

    The purpose of this study is evaluate the safety of allogeneic adipose derived mesenchymal stem cell (AMSC) use during hemodialysis arteriovenous fistula and ...

  10. Cell, Serum, and Buccal Bank for Patients with Chronic Myeloid Disorders and Acute Leukemia - Mayo Clinic

    About this study. This study is being done to store blood, buccal (cheek) cells, genetic material including DNA (deoxyribonucleic acid) and RNA (ribonucleic ...